Which medications in the drug class Antineoplastics, Tyrosine Kinase Inhibitor are used in the treatment of B-Cell Lymphoma?

Updated: Feb 23, 2021
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Antineoplastics, Tyrosine Kinase Inhibitor

Ibrutinib received accelerated approval from the FDA for marginal zone lymphoma following analysis of phase 2 data in 63 patients who had a median follow-up of 19.4 months. Of these patients, 3% (n=2) treated with ibrutinib achieved complete responses (CR) and 45% (n=27) achieved partial responses (PR). Overall, 78% of patients experienced tumor reduction. Median progression-free survival was 14.2 months. [37]

Ibrutinib (Imbruvica)

Bruton’s tyrosine kinase (BTK) inhibitor forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways.

BTK’s role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. It is indicated for mantle cell lymphoma in patients who have received at least 1 previous therapy. It also indicated for marginal zone lymphoma (MZL) in patients who require systemic therapy and have received at least 1 prior anti-CD20-based therapy.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!